Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors

Infection

Volumn 45, Issue 1, 2017, Pages 103-106

  Boglione, Lucio ^a,b   Pinna, Simone Mornese ^a,b   Cardellino, Chiara Simona ^a,b   De Nicolò, Amedeo ^a,b   Cusato, Jessica ^a,b   Carcieri, Chiara ^a,b   Cariti, Giuseppe ^a,b   Di Perri, Giovanni ^a,b   D’Avolio, Antonio ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

Cirrhotic; Daclatasvir; HCV; Protease inhibitors; Ribavirin

Indexed keywords

DACLATASVIR; DRUG; INTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHILD PUGH SCORE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; LIVER CIRRHOSIS; MALE; COMPLICATION; HEPATITIS C, CHRONIC; MIDDLE AGED;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; SOFOSBUVIR;

EID: 84995493876     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-016-0962-3     Document Type: Article

References (7)

1. WHO. WHO fact sheet No. 164. 2012. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 25 July 2016
2. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.
4. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.
5. Gerber L, Welzel TM, Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int. 2013;33:85–92.
6. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2013;383:515–23.
7. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.